Table 1.
Trials targeting the ALIC
| ALIC | ||||
|---|---|---|---|---|
| Reference | Responders (ratio) | Follow-up | Patients included elsewhere | Y-BOCS Reduction |
| Gabriels, 2003 [24] | 2/3 | 33 months | 1 patient included in Nuttin, [13] | 35.5% |
| Anderson & Ahmed, 2003 [25] | 1/1 | 3 months | 79.4% | |
| Nuttin, 2003* [23] | 3/6 | 31 months | 3 patients included in Gabriels, [24] | 17.6-72% |
| Abelson, 2005* [26] | 2/4 | 23 months | 0-73.3% | |
| Servello, 2009 * [27] | 2/4 | 51 months | 8.7-60.5% | |
| Mean | 75% | 46.5% | ||
ALIC: anterior limb of the internal capsule. Responders’ ratio: responders defined as 35% improvement in Y-BOCS score or more. Follow-up: latest follow-up reported. Patients included elsewhere: Number of patients of which the data has been reported before and corresponding publication. Y-BOCS reduction: mean reduction for new patients at latest follow-up or reduction range if individual data not available. *Data not included in pooled means due to missing information/republished data.